MREO
Mereo BioPharma Group plc
NASDAQ · Healthcare · Biotechnology · GB
$0.25
−8.16%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$39.92M
MomentumView details →
1D Return
−8.16%
YTD Return
−37.75%
RSI (14)
39.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$39.92M
RSI (14)
39.2
MomentumView details →
1D Return
−8.16%
YTD Return
−37.75%
SummaryUpdated Jun 1, 2026
Mereo BioPharma Group plc (NASDAQ:MREO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company went public on NASDAQ in April 2019. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, with a pipeline of antibody-based treatments and small molecule drugs currently in various phases of clinical trials. As a development-stage company, Mereo does not yet generate product revenue and is funded through equity financing while advancing its therapeutic candidates through regulatory approval processes.
Similar companies
Latest newsMore news →
Mereo BioPharma Group plc received a notice from NASDAQ on 2026-08-18 indicating non-compliance with the minimum bid price requirement under Rule 5550(a)(2), with a compliance deadline of 2027-02-16.17d agoMereo BioPharma Group plc reported its Q2 2026 financial results, with zero revenue, a net loss of $7.005 million, and diluted EPS of -$0.01, while holding approximately $30 million in cash and cash equivalents as of June 30, 2026.25d ago